Artiva Biotherapeutics (ARTV) News Today $11.11 +1.11 (+11.10%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Wellington Management Group LLP Invests $2.91 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Wellington Management Group LLP bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 194,108 shares of the compaDecember 18, 2024 | marketbeat.comFDA ARMAT status for Affimed and Artiva’s lymphoma combo therapyDecember 6, 2024 | msn.comSamsara BioCapital LLC Acquires New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Samsara BioCapital LLC bought a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 291,666 shares of the company's stock, valued at approxDecember 5, 2024 | marketbeat.comRA Capital Management L.P. Takes $152.23 Million Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)RA Capital Management L.P. bought a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,853,302 shares of the company's stock, valued at approximately $152,234,000.December 5, 2024 | marketbeat.comRTW Investments LP Takes $2.30 Million Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)RTW Investments LP bought a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 148,844 shares of the company's stock, valued at approximately $December 5, 2024 | marketbeat.comAcuta Capital Partners LLC Takes $680,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)Acuta Capital Partners LLC purchased a new stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 44,000 shares of the company'sNovember 28, 2024 | marketbeat.comCantor Fitzgerald Forecasts ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects thaNovember 18, 2024 | marketbeat.comWedbush Has Bearish Forecast for ARTV FY2024 EarningsArtiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush cut their FY2024 earnings per share estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per shareNovember 15, 2024 | marketbeat.comArtiva Biotherapeutics (NASDAQ:ARTV) Announces Earnings ResultsArtiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24).November 14, 2024 | marketbeat.comArtiva Biotherapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | tipranks.comArtiva Biotherapeutics, Inc.: Strong Buy Rating Supported by Robust Autoimmune Pipeline and Financial StabilityNovember 13, 2024 | markets.businessinsider.comNeedham & Company LLC Reiterates "Buy" Rating for Artiva Biotherapeutics (NASDAQ:ARTV)Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday.November 13, 2024 | marketbeat.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from TD CowenNovember 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 12, 2024 | globenewswire.comArtiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 11, 2024 | globenewswire.comArtiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsOctober 22, 2024 | globenewswire.comArtiva Biotherapeutics (NASDAQ:ARTV) Shares Down 5.4% - Time to Sell?Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4% - Time to Sell?October 15, 2024 | marketbeat.comArtiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comBuy Rating Affirmed for Artiva Biotherapeutics on Promising AlloNK Developments and Trial OptimismSeptember 4, 2024 | markets.businessinsider.comArtiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by WedbushWedbush reaffirmed an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday.August 31, 2024 | marketbeat.comBuy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong FinancialsAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc. (ARTV) Receives a Buy from WedbushAugust 30, 2024 | markets.businessinsider.comArtiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | finanznachrichten.deArtiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 30, 2024 | markets.businessinsider.comThis Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative TreatmentAugust 29, 2024 | fool.comArtiva Biotherapeutics, Inc.'s (NASDAQ:ARTV) Quiet Period Will End on August 28thArtiva Biotherapeutics' (NASDAQ:ARTV - Get Free Report) quiet period is set to expire on Wednesday, August 28th. Artiva Biotherapeutics had issued 13,920,000 shares in its public offering on July 19th. The total size of the offering was $167,040,000 based on an initial share price of $12.00. During Artiva Biotherapeutics' quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.August 21, 2024 | marketbeat.comArtiva Biotherapeutics shares get Overweight ratingAugust 15, 2024 | uk.investing.comAnalysts Set Expectations for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV)Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at Wedbush issued their Q2 2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Tuesday, August 13th. Wedbush analyst D. Nierengarten expects that the company will earn ($1.5August 15, 2024 | marketbeat.comArtiva Biotherapeutics, Inc. (ARTV)August 13, 2024 | finance.yahoo.comBuy Rating Affirmed: Artiva Biotherapeutics’ Promising AlloNK Cell Therapy in the Autoimmune SpaceAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Artiva Biotherapeutics Amid Promising NK Cell Therapy DevelopmentsAugust 13, 2024 | markets.businessinsider.comArtiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish PitchAugust 13, 2024 | benzinga.comJefferies Financial Group Begins Coverage on Artiva Biotherapeutics (NASDAQ:ARTV)Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday. They set a "buy" rating and a $21.00 price target for the company.August 13, 2024 | marketbeat.comArtiva Biotherapeutics Inc ARTVJuly 31, 2024 | morningstar.comInsider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up SharesJuly 28, 2024 | 247wallst.comArtiva Biotherapeutics Inc (ARTV)July 23, 2024 | investing.comInsider Buying: Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Buys 416,666 Shares of StockJuly 23, 2024 | insidertrades.com Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW ARTV Media Mentions By Week ARTV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARTV News Sentiment▼1.540.60▲Average Medical News Sentiment ARTV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARTV Articles This Week▼11▲ARTV Articles Average Week Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADPT News PSTX News IMTX News REPL News LENZ News RLAY News AVXL News AUTL News CGEM News TECX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARTV) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
